HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 108 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2013. The put-call ratio across all filers is 1.49 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $4,319,000 | -34.3% | 500,449 | -27.9% | 0.30% | -26.3% |
| Q1 2016 | $6,576,000 | -22.0% | 694,436 | +42.8% | 0.40% | -14.8% |
| Q4 2015 | $8,427,000 | +29.0% | 486,276 | 0.0% | 0.47% | +111.2% |
| Q3 2015 | $6,531,000 | -57.0% | 486,276 | -27.7% | 0.22% | -2.6% |
| Q2 2015 | $15,194,000 | +25.0% | 672,883 | -21.0% | 0.23% | -66.0% |
| Q1 2015 | $12,157,000 | -37.3% | 851,305 | -57.7% | 0.68% | -30.2% |
| Q4 2014 | $19,398,000 | -47.4% | 2,010,186 | -50.4% | 0.97% | -48.9% |
| Q3 2014 | $36,906,000 | -18.0% | 4,055,590 | -11.0% | 1.90% | -22.0% |
| Q2 2014 | $45,014,000 | -16.0% | 4,556,090 | +8.0% | 2.44% | -20.6% |
| Q1 2014 | $53,600,000 | -15.2% | 4,218,800 | 0.0% | 3.07% | -17.3% |
| Q4 2013 | $63,240,000 | +26.7% | 4,218,800 | -6.7% | 3.71% | +9.2% |
| Q3 2013 | $49,899,000 | +36.4% | 4,519,800 | -1.8% | 3.40% | +38.1% |
| Q2 2013 | $36,582,000 | – | 4,601,500 | – | 2.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |